Monjuvi Demonstrates Long-Term Efficacy for Individuals With R/R DLBCL
Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.
Data from the ongoing L-MIND study (NCT02399085) demonstrated that tafasitamab-cxix (Monjuvi; MorphoSys US) plus lenalidomide followed by tafasitamab-cxix as a monotherapy had long-term efficacy in individuals with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated for at least 2 years, including 6 patients who were on treatment for 5 years or longer.
Additionally, the frequency of adverse events (AEs) decreased after the individuals transitioned from combination therapy to monotherapy.
The data wereas presented during a posted session at the 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) in Houston, Texas.
“"The body of data presented at SOHO shows the long-term duration of response to tafasitamab in some patients with [R/R DLBCL] not eligible for autologous stem-cell transplant,”" Malte Peters, MD, chief research and development officer at MorphoSys, said in a statement. “"These long-term follow-up results for L-MIND reaffirm our belief that tafasitamab plus lenalidomide remains the in-practice, outpatient targeted immunotherapy of choice for this group of patients.”"
For the study, the data cutoff date was February 15, 2022. Out of 80 individuals, 27 had undergone treatment for at least 2 years, with a median duration of treatment being of 4.3 years. Of the 27, 23 individuals were alive at the data cutoff with 13 remaining on the treatment, including 6 who were on the treatment for at least 5 years.
Investigators observed a complete response for 23 of the 27 individuals, including 4 who were refractory to their primary therapy. There wereas an additional 4 individuals who had a partial response, with 2 who were still on the treatment at the data cutoff.
“"The new long-term follow-up results from L-MIND at SOHO 2022 highlight the potential of tafasitamab in providing long-term efficacy in patients with [R/R DLBCL],”" Johannes Duell, MD, from the University Hospital Wuerzburg Medical Clinic and Polyclinic, said in the statement.
“"The fact that 6 of the 27 patients who responded received treatment for 5 or more years – withyears, with another 7 patients nearing the 5-year mark, – points to the durable response induced by tafasitamab. This response durability represents the type of data that offers oncologists confidence when recommending therapies to their patients,.”" Duell said.
Investigators reported that the majority of AEs were grade 1 or 2 during both the combination and monotherapy treatment. Additionally, individuals experienced a lower frequency of all-grade and grade 3 or higher AEs during monotherapy.
The most common AEs with the combination therapy were diarrhea and neutropenia, which declined after the individuals switched to the monotherapy.
Those 2 AEs remained the most common AEs for the first 2 years of monotherapy, investigators reportedsaid.
In the United States, tafasitamab-cxix is FDA-approved by the FDA in combination with lenalidomide for the treatment of adult individuals with R/R DLBCL, including DLBCL arising from low-grade lymphoma, and for those who are not eligible for autologous stem cell transplant.
MorphoSys presents new long-term data from L-MIND suggesting durable response to treatment with Monjuvi (tafasitamab-cxix) for patients with R/R DLBCL. News release. Yahoo!. September 28, 2022. Accessed September 29, 2022. https://finance.yahoo.com/news/morphosys-presents-long-term-data-200100580.html